Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis

Harshita Paripati, Nina J. Karlin, Steven E. Schild, Sujay A. Vora, Amylou Dueck, Helen J Ross

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objectives: Concurrent combined modality therapy is optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) and is given with curative intent. However, elderly patients (≥ 75) are often undertreated, despite good performance status (PS). This study evaluated the treatment, outcomes and survival in elderly patients with stage III NSCLC versus patients < 75. years old. Materials and Methods: A retrospective review of data from the Lung Cancer Registry at Mayo Clinic Arizona (MCA) was conducted. Patients with newly diagnosed stage III NSCLC from 1998 to 2006 were analyzed for type of therapy and outcomes. Results: Three hundred and eighty-nine patients with newly diagnosed stage III NSCLC were identified from 1998 to 2006. Two hundred and forty-three (62%) patients were < 75. years old, and 146 patients (38%) were ≥ 75. years old. Among 374 eligible patients, 45% of patients < 75. years old received combined chemoradiation therapy vs. only 21% of patients ≥ 75. years old (p< 0.0001). The median survival in the < 75 age group was 14.5. months vs. 10.1. months in the ≥ 75 age group (p= 0.0014). In the < 75 age group, median survival was 15.0. months in patients who received combined modality treatment vs. 14.1. months in the other treatments group (p= 0.02). In the elderly group, median survival was 19.9. months in the combined modality group vs. 7.8. months in the other treatments group (p= 0.0048). Conclusion: Our results confirm that older patients are less likely to receive optimal therapy, regardless of functional status. Prospective studies are desperately needed to help improve management of the burgeoning geriatric oncology population.

Original languageEnglish (US)
Pages (from-to)104-110
Number of pages7
JournalJournal of Geriatric Oncology
Volume3
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Survival
Therapeutics
Age Groups
Combined Modality Therapy
Geriatrics
Registries
Lung Neoplasms
Prospective Studies

Keywords

  • Elderly
  • Non-small cell lung cancer
  • Performance status

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Oncology

Cite this

Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis. / Paripati, Harshita; Karlin, Nina J.; Schild, Steven E.; Vora, Sujay A.; Dueck, Amylou; Ross, Helen J.

In: Journal of Geriatric Oncology, Vol. 3, No. 2, 04.2012, p. 104-110.

Research output: Contribution to journalArticle

@article{5eb457e2d21d479ca297c83dd8e1bd18,
title = "Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis",
abstract = "Objectives: Concurrent combined modality therapy is optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) and is given with curative intent. However, elderly patients (≥ 75) are often undertreated, despite good performance status (PS). This study evaluated the treatment, outcomes and survival in elderly patients with stage III NSCLC versus patients < 75. years old. Materials and Methods: A retrospective review of data from the Lung Cancer Registry at Mayo Clinic Arizona (MCA) was conducted. Patients with newly diagnosed stage III NSCLC from 1998 to 2006 were analyzed for type of therapy and outcomes. Results: Three hundred and eighty-nine patients with newly diagnosed stage III NSCLC were identified from 1998 to 2006. Two hundred and forty-three (62{\%}) patients were < 75. years old, and 146 patients (38{\%}) were ≥ 75. years old. Among 374 eligible patients, 45{\%} of patients < 75. years old received combined chemoradiation therapy vs. only 21{\%} of patients ≥ 75. years old (p< 0.0001). The median survival in the < 75 age group was 14.5. months vs. 10.1. months in the ≥ 75 age group (p= 0.0014). In the < 75 age group, median survival was 15.0. months in patients who received combined modality treatment vs. 14.1. months in the other treatments group (p= 0.02). In the elderly group, median survival was 19.9. months in the combined modality group vs. 7.8. months in the other treatments group (p= 0.0048). Conclusion: Our results confirm that older patients are less likely to receive optimal therapy, regardless of functional status. Prospective studies are desperately needed to help improve management of the burgeoning geriatric oncology population.",
keywords = "Elderly, Non-small cell lung cancer, Performance status",
author = "Harshita Paripati and Karlin, {Nina J.} and Schild, {Steven E.} and Vora, {Sujay A.} and Amylou Dueck and Ross, {Helen J}",
year = "2012",
month = "4",
doi = "10.1016/j.jgo.2011.12.002",
language = "English (US)",
volume = "3",
pages = "104--110",
journal = "Journal of Geriatric Oncology",
issn = "1879-4068",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Multimodality therapy improves survival in elderly patients with locally advanced non-small cell lung cancer-A retrospective analysis

AU - Paripati, Harshita

AU - Karlin, Nina J.

AU - Schild, Steven E.

AU - Vora, Sujay A.

AU - Dueck, Amylou

AU - Ross, Helen J

PY - 2012/4

Y1 - 2012/4

N2 - Objectives: Concurrent combined modality therapy is optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) and is given with curative intent. However, elderly patients (≥ 75) are often undertreated, despite good performance status (PS). This study evaluated the treatment, outcomes and survival in elderly patients with stage III NSCLC versus patients < 75. years old. Materials and Methods: A retrospective review of data from the Lung Cancer Registry at Mayo Clinic Arizona (MCA) was conducted. Patients with newly diagnosed stage III NSCLC from 1998 to 2006 were analyzed for type of therapy and outcomes. Results: Three hundred and eighty-nine patients with newly diagnosed stage III NSCLC were identified from 1998 to 2006. Two hundred and forty-three (62%) patients were < 75. years old, and 146 patients (38%) were ≥ 75. years old. Among 374 eligible patients, 45% of patients < 75. years old received combined chemoradiation therapy vs. only 21% of patients ≥ 75. years old (p< 0.0001). The median survival in the < 75 age group was 14.5. months vs. 10.1. months in the ≥ 75 age group (p= 0.0014). In the < 75 age group, median survival was 15.0. months in patients who received combined modality treatment vs. 14.1. months in the other treatments group (p= 0.02). In the elderly group, median survival was 19.9. months in the combined modality group vs. 7.8. months in the other treatments group (p= 0.0048). Conclusion: Our results confirm that older patients are less likely to receive optimal therapy, regardless of functional status. Prospective studies are desperately needed to help improve management of the burgeoning geriatric oncology population.

AB - Objectives: Concurrent combined modality therapy is optimal treatment for patients with stage III non-small cell lung cancer (NSCLC) and is given with curative intent. However, elderly patients (≥ 75) are often undertreated, despite good performance status (PS). This study evaluated the treatment, outcomes and survival in elderly patients with stage III NSCLC versus patients < 75. years old. Materials and Methods: A retrospective review of data from the Lung Cancer Registry at Mayo Clinic Arizona (MCA) was conducted. Patients with newly diagnosed stage III NSCLC from 1998 to 2006 were analyzed for type of therapy and outcomes. Results: Three hundred and eighty-nine patients with newly diagnosed stage III NSCLC were identified from 1998 to 2006. Two hundred and forty-three (62%) patients were < 75. years old, and 146 patients (38%) were ≥ 75. years old. Among 374 eligible patients, 45% of patients < 75. years old received combined chemoradiation therapy vs. only 21% of patients ≥ 75. years old (p< 0.0001). The median survival in the < 75 age group was 14.5. months vs. 10.1. months in the ≥ 75 age group (p= 0.0014). In the < 75 age group, median survival was 15.0. months in patients who received combined modality treatment vs. 14.1. months in the other treatments group (p= 0.02). In the elderly group, median survival was 19.9. months in the combined modality group vs. 7.8. months in the other treatments group (p= 0.0048). Conclusion: Our results confirm that older patients are less likely to receive optimal therapy, regardless of functional status. Prospective studies are desperately needed to help improve management of the burgeoning geriatric oncology population.

KW - Elderly

KW - Non-small cell lung cancer

KW - Performance status

UR - http://www.scopus.com/inward/record.url?scp=84858792116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858792116&partnerID=8YFLogxK

U2 - 10.1016/j.jgo.2011.12.002

DO - 10.1016/j.jgo.2011.12.002

M3 - Article

AN - SCOPUS:84858792116

VL - 3

SP - 104

EP - 110

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

SN - 1879-4068

IS - 2

ER -